There is one clinical trial.
This is a Phase 1 Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults with COVID-19
Description: AE frequency in each cohort and treatment groupMeasure: Assess safety of UNI911 INHALATION in healthy volunteers: AE frequency Time: Up to Day 6
Description: Maximum concentration of active drug molecules in blood (Cmax)Measure: Pharmacokinetic Parameters: Cmax Time: Up to Day 4 of participant treatment
Description: Time to reach maximum level (Tmax)Measure: Pharmacokinetic Parameters: Tmax Time: Up to Day 4 of participant treatment
Description: Area Under the Curve of drug level in blood versus time (AUC)Measure: Pharmacokinetic Parameters: AUC Time: Up to Day 4 of participant treatment
Description: Half lifeMeasure: Pharmacokinetic Parameters: Half life Time: Up to Day 4 of participant treatment
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports